News

Maxigesic Rapid® tablets gain US FDA approval

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces the US Food and Drug Administration has approved a rapid release tablet form of Maxigesic for the management of mild to moderate acute pain in the US.

Financial Results For Half Year Ended 30 September 2020

AFT to develop antibiotic eye drop

AFT Pharmaceuticals to develop antibiotic eye drop

2023 New Year letter to investors

AFT Pharmaceuticals releases New Year letter to shareholders.

AFT extends growth investment as sales surge

AFT PHARMACEUTICALS LTD FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2022

AFT Pharmaceuticals to announce half year interim results on Thursday November 24 2022

AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC).

Pascomer Trial Results Timber Termination

AFT Completes Pascomer Clinical Study and Takes Back Rights in North America

AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC).

Filter

28/10/2009

Kiwi Co. pops pill into US$20b pain-relief market

New Zealanders will find a home-grown answer to pain relief on the shelves at their local pharmacy this month with the launch of a new drug that represents a world breakthrough.